Manulife (MFC) Q4 2025 earnings review
Record Year, But Asset Bleed Accelerates
Manulife delivered a headline beat with record full-year core earnings of $7.5B and a 10.2% dividend hike, but the surface-level strength masks a deepening fracture in Global Wealth & Asset Management (WAM). While Asia continues to power the P&L (Core Earnings +24%), Global WAM suffered a massive $9.5B net outflow in Q4, accelerating from Q3's $6.2B bleed. The U.S. segment is also dragging, with earnings down 22% due to mortality claims. The bull case rests entirely on Asia executing perfectly and capital returns (buybacks/dividends); the bear case is that the asset management franchise is shrinking despite record equity markets.
🐂 Bull Case
Asia is firing on all cylinders. Core earnings jumped 24% YoY, and New Business CSM (future profit) rose 19%. The region now accounts for a dominant share of growth, with strong execution in Hong Kong and Japan.
Management hiked the dividend by 10.2% and announced a new 2.5% share buyback (NCIB). With a strong LICAT ratio (136%) and core ROE hitting 17.1%, MFC is prioritizing shareholder yield.
🐻 Bear Case
Global WAM is bleeding assets at an alarming rate. Net outflows worsened from $6.2B in Q3 to $9.5B in Q4. Losing $14.3B in assets during a bull market year is a significant operational failure.
The U.S. segment is becoming a drag. Core earnings fell 22% YoY in Q4, following a 20% drop in Q3. Unfavorable mortality experience and lower investment spreads are persistent headwinds.
⚖️ Verdict: ⚪
Neutral. While the Asian insurance business is world-class and capital returns are attractive, the accelerating outflows in Asset Management and persistent weakness in the U.S. prevent a higher grade. You cannot ignore a $9.5B quarterly outflow hole.
Key Themes
Asset Management Exodus
Decelerating. The trend in Global WAM flows is ugly. After positive flows in 25H1, the segment turned negative in Q3 (-$6.2B) and collapsed further in Q4 (-$9.5B). Retail investors pulled $5.6B and Retirement plans redeemed $7.2B. While Core Earnings in WAM grew due to markets/fees, the organic growth engine is broken.
Asia's Profit Engine
Accelerating. Asia continues to be the savior. Core earnings grew 24% YoY to $564M (USD). New Business CSM grew 19%. Despite a slight dip in APE sales (-3%) due to tough comps in Hong Kong, the profitability profile (NBV margin) is improving to 41.2%.
U.S. Mortality & Spreads
Decelerating. The U.S. segment is struggling. Core earnings dropped 22% to $229M USD. Management cited 'unfavorable life insurance claims experience' and 'lower investment spreads.' This echoes Q3 issues, suggesting structural pressure rather than a one-off blip.
Future Profit (CSM) Build
Stable/Accelerating. Total New Business CSM grew 21% YoY to $1.02B in Q4. This metric represents future earnings stored on the balance sheet. High growth here, particularly in Canada (+16%) and U.S. (+34%), suggests that while current U.S. earnings are down, the new business being written is highly profitable.
ALDA Portfolio Headwinds
Stable. The Alternative Long-Duration Assets (ALDA) portfolio—real estate, private equity, timber—continues to drag on Net Income (though excluded from Core Earnings). Net income fell $100M YoY in Q4 partially due to lower-than-expected ALDA returns. This remains a volatile 'non-core' item that investors must monitor for book value erosion.
Expense Discipline
Accelerating. Despite the revenue pressures in WAM, the segment's Core EBITDA margin expanded 60bps to 29.2%. Across the board, Core ROE improved to 17.1%. Management is effectively using cost controls and AI/digitization to protect margins even where top-line is challenged.
Other KPIs
Accelerating. Improved 0.6 percentage points YoY. This is closing in on the medium-term target of 18%+, driven by capital management (buybacks) and strong Asia earnings.
Stable. Up 8% YoY. While APE sales were flat (-1%), the value of that business increased, indicating better pricing discipline and a shift toward higher-margin products.
Stable. Down slightly from 137% in Q3, but remains extremely robust (well above regulatory minimums), supporting the dividend hike and NCIB.
Guidance
Stable. Management reaffirmed confidence in achieving targets. With FY25 Core ROE at 16.5% and Q4 at 17.1%, they are converging on this target.
Stable. FY25 Core EPS growth was 8%. Achieving double digits requires stabilizing the U.S. business and reversing WAM outflows, as buybacks alone likely won't bridge the gap.
Stable. The ratio is hovering around mid-40s. Continued AI adoption (GenAI tools deployed in 9 markets) is the primary lever cited to achieve this.
Key Questions
Stemming the WAM Bleed
Global WAM outflows accelerated to $9.5B this quarter. Is this purely macro-driven (rates/markets), or is there a structural competitive issue in your retail and retirement offerings?
U.S. Mortality Persistence
U.S. core earnings have been hit by unfavorable claims experience for multiple quarters now (-22% in Q4). At what point does 'volatility' become a baseline assumption requiring a reserve adjustment?
Comvest Integration
With the Comvest acquisition closing in Q4 (implied by flows impact mention), how much of the WAM inflow/outflow volatility is organic vs. deal-related?
China/Hong Kong Outlook
Hong Kong sales dropped 3% YoY. Given the economic uncertainty in mainland China, are you seeing a shift in the 'Mainland Chinese Visitor' (MCV) demand that powered 2024?